Ratto G B, Capponi G, De Grandi R, Augeri C, Secco G B, Fardelli R
Istituto di Clinica Chirurgica I, Università di Genova.
Minerva Chir. 1990 Oct 31;45(20):1265-72.
The present study has been carried out in order to evaluate the role of tumor markers in the presurgical assessment of patients with bronchial carcinoma. The carcinoembryonic antigen (CEA), the neuron specific enolase (NSE), the tissue polypeptide antigen (TPA), the carbohydrate antigen 19-9 (CA 19-9) and the carbohydrate antigen 50 (CA 50) have been preoperatively measured in 133 subjects with potentially resectable lung cancers, and in 75 healthy smokers. Sixty-one patients had squamous cell carcinoma, 55 adenocarcinoma and 17 small cell carcinoma. Lobectomy (or bilobectomy) was performed in 74 cases, pneumonectomy in 36 cases, exploratory thoracotomy in 15 cases and a palliative resection in 8 cases. When individual markers were considered, TPA showed the highest sensitivity (85%) and CA 19-9 the lowest sensitivity (11%). Specificity was uniformly superior to 90%. When marker associations were considered, the combined measurement of TPA and NSE gave the best results: both the sensitivity and specificity rates approached 90%. The application of the TPA-NSE association allowed detection of 94% of small cell carcinomas, 89% of adenocarcinomas and 85% of squamous cell carcinomas. A positive correlation was found between the complete resectability of lung cancer and serum levels of CEA, CA 50 and CA 19-9. By using the discriminant analysis, a statistical model yielding identification of about 74% of patients with tumors which were judged potentially resectable according to the pre-operative non-invasive diagnostic procedures and were found to be unresectable at thoracotomy, has been get available.
本研究旨在评估肿瘤标志物在支气管癌患者术前评估中的作用。对133例可能可切除肺癌患者及75例健康吸烟者术前检测癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、组织多肽抗原(TPA)、糖类抗原19-9(CA 19-9)和糖类抗原50(CA 50)。61例为鳞状细胞癌,55例为腺癌,17例为小细胞癌。74例行肺叶切除术(或双肺叶切除术),36例行全肺切除术,15例行 exploratory thoracotomy(此词有误,推测为“剖胸探查术”),8例行姑息性切除术。单独考虑各个标志物时,TPA敏感性最高(85%),CA 19-9敏感性最低(11%)。特异性均优于90%。考虑标志物联合检测时,TPA和NSE联合检测结果最佳:敏感性和特异性均接近90%。TPA-NSE联合检测可检测出94%的小细胞癌、89%的腺癌和85%的鳞状细胞癌。发现肺癌的完全可切除性与CEA、CA 50和CA 19-9的血清水平呈正相关。通过判别分析,已建立一个统计模型,可识别约74%的肿瘤患者,这些患者根据术前非侵入性诊断程序判断可能可切除,但在开胸手术中发现不可切除。